Bu sayfada
ORMP Oramed Pharmaceuticals Inc. - Common Stock
NASDAQ · Pharmaceuticals · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 10, 2026
$4,49
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$2,0952 haftanın en düşüğü
$5,4752 haftanın en yükseği
Piyasa Değeri (MRQ)
$186M
P/E
0.0
Hisse Başına Kâr
$1.50
Gelir
$2M
rozetleriniz
52 Haftlık Aralık
$2–$5
Analist Derecelendirmesi
HOLD
Fiyat Hedefi
$7
P/E
0.0
ROE
37.0%
Net Kâr Marjı
3202.5%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
ORMP Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$4.49
Piyasa Değeri (MRQ)
$186M
P/E
0.0
Hisse Başına Kâr
$1.50
Gelir
$2M
ROE
37.0%
52 Haftlık Aralık
$2–$5
ORMP Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 23 Ocak 2013 | 1-for-12 | Ters |
Oramed Pharmaceuticals Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
Subsidiaries
OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriPharmaceuticals
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$2M2017-08-31 → 2025-12-31
Hisse Başına Kâr$1.502022-12-31 → 2025-12-31
Serbest Nakit Akışı$-9M2019-08-31 → 2025-12-31
Net kar marjı3202.5%2019-08-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | ORMP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | 0.05Y ort. ≈0.1 | ≈0.1 | · | · | |
| P/S (F/S) | 0.15Y ort. ≈100.5 | ≈100.5 | · | · | |
| F/D (MRQ) | 0.65Y ort. ≈1.4 | ≈1.4 | 1.2 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | -35.65Y ort. ≈-12.6 | ≈-12.6 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -35.65Y ort. ≈-12.8 | ≈-12.8 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 0.05Y ort. ≈1.2 | ≈1.2 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | ORMP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Gross Margin (Brüt Kar Marjı) | 0.65% | · | · | · | |
| Operating Margin (Faaliyet Kâr Marjı) | -754.4%5Y ort. ≈-1144.4% | ≈-1144.4% | -12.4% | Zayıf | |
| EBITDA Margin (FAVÖK Marjı) | -754.4%5Y ort. ≈-1144.4% | ≈-1144.4% | 2.5% | Zayıf | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | 3766.2% | · | 38.2% | En üst düzey | |
| Net Profit Margin (Net Kâr Marjı) | 3202.5%5Y ort. ≈739.2% | ≈739.2% | 30.4% | En üst düzey | |
| ROA | 33.2%5Y ort. ≈4.6% | ≈4.6% | -1.5% | En üst düzey | |
| ROE | 37.0%5Y ort. ≈5.6% | ≈5.6% | -7.6% | En üst düzey | |
| ROIC | -6.4% | · | · | · |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | ORMP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 5.05Y ort. ≈12.5 | ≈12.5 | 9.6 | Ortalamanın altında | |
| Quick Ratio (Cari Oran) | 2.75Y ort. ≈1.5 | ≈1.5 | 3.1 | Ortalamanın altında |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | ORMP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -50.4% | · | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -9.6% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | ORMP | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.0 | ≈0.0 | 0.4 | Zayıf |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Temettüler Temettü verimi, ödeme oranı, temettü geçmişi, 5 Yıllık CAGR
| Ex-tarihi | Miktar | Para Birimi | Temettü Verimi |
|---|---|---|---|
| Oca 16, 2026 | $0,25 | USD | ≈6.8% |
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
472.3%
Sonraki Rapor
Kas 11, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 12, 2026 | $1.84 | $0.44 | 319.5% |
| 31 Aralık 2025 | $0.24 | $0.00 | — | |
| 30 Eylül 2025 | $1.12 | $-0.04 | 2845.1% | |
| 30 Haziran 2025 | $0.31 | $-0.04 | 859.8% | |
| 31 Mart 2025 | $-0.19 | $-0.01 | -1762.7% | |
| 31 Aralık 2024 | $0.00 | $-0.03 | 100.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | · | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Cost of Revenue | $2M | · | · | · | · | · | $90.0K | $-86.0K | $187.0K | |
| Gross Profit | $13.0K | · | · | · | · | · | · | · | · | |
| R&D Expense | $6M | $6M | $9M | $28M | · | $10M | $14M | $12M | $10M | |
| SG&A Expense | $9M | $6M | $8M | $14M | · | $4M | $4M | $4M | $3M | |
| Operating Income | $-15M | $-13M | $-16M | $-41M | · | $-12M | $-15M | $-14M | $-11M | |
| Interest Expense | · | · | $2M | · | · | · | · | · | · | |
| Interest Income | · | · | $10.0K | · | · | · | · | · | · | |
| Other Non-op | $-606.0K | $-27.0K | $13.3K | $3M | · | · | · | · | · | |
| Pretax Income | $75M | $-16M | $5M | $-38M | · | $-12M | $-14M | $-13M | $-10M | |
| Income Tax | $11M | $3M | · | $100.0K | · | · | $300.0K | · | $400.0K | |
| Net Income | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| EPS (Basic) | $1.53 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| EPS (Diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| Shares (Basic) | 41,402,997 | 40,850,446 | 40,315,068 | 38,997,649 | · | · | · | · | · | |
| Shares (Diluted) | 42,418,644 | 40,850,446 | 40,566,901 | 38,997,649 | · | · | · | · | · | |
| EBITDA | $-15M | · | $-16M | $-41M | · | $-12M | $-15M | · | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $54M | $9M | $40M | · | $19M | $3M | $5M | $4M | |
| Short-term Investments | $5M | $3M | · | · | $8M | $3M | · | $5M | · | |
| Prepaid Expense | $3M | $1M | $537.0K | $1M | · | $611.0K | $1M | $574.0K | · | |
| Current Assets | $133M | $143M | $163M | $157M | $148M | $41M | $33M | $31M | · | |
| PP&E (Net) | $586.0K | $698.0K | $873.0K | $815.0K | $388.0K | $99.0K | $24.0K | $17.0K | · | |
| Other Non-current Assets | $44.0K | $32.0K | $27.0K | · | · | · | · | · | · | |
| Total Assets | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Accounts Payable | $443.0K | $789.0K | $551.0K | $4M | $5M | $2M | $3M | $2M | · | |
| Accrued Liabilities | $1M | $402.0K | $605.0K | · | · | · | · | · | · | |
| Short-term Debt | $652.0K | $329.0K | $51M | · | · | · | $3M | $2M | · | |
| Current Liabilities | $19M | $6M | $53M | $6M | $7M | $5M | $5M | $5M | · | |
| Capital Leases | $540.0K | $156.0K | $342.0K | $647.0K | $370.0K | $31.0K | · | · | · | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | $60.0K | $63.0K | · | · | $211.0K | $271.0K | $313.0K | · | |
| Long-term Debt | · | · | · | $25.0K | $12M | · | $10M | $11M | · | |
| Total Debt | · | · | $51M | · | · | · | $3M | · | · | |
| Common Stock | $472.0K | $480.0K | $485.0K | $476.0K | $459.0K | $284.0K | $208.0K | $207.0K | · | |
| Paid-in Capital | · | · | · | $314M | $293M | $125M | · | · | · | |
| Retained Earnings | $-123M | $-177M | $-158M | $-163M | $-127M | $-93M | $-81M | $-69M | · | |
| AOCI | · | · | · | · | · | · | · | $702.0K | · | |
| Stockholders' Equity | $200M | $145M | $164M | $152M | $166M | $33M | $19M | $31M | $19M | |
| Liabilities + Equity | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Shares Outstanding | 39,275,006 | 39,920 | 40,339,000 | 39,564,000 | 38,158 | 23,675,530 | 17,383,359 | 17,369,875 | · |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | $4M | $12M | · | $465.0K | $808.0K | $2M | $2M | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-9M | $-8M | $-10M | $-28M | · | $-12M | $-13M | $-15M | $-6M | |
| CapEx | $9.0K | $18.0K | $254.0K | $496.0K | · | $82.0K | $15.0K | $5.0K | $7.0K | |
| Investing Cash Flow | $5M | $106M | $-73M | $30M | · | $5M | $11M | $-7M | $4M | |
| Stock Issued | · | · | $2M | $12M | · | · | · | · | · | |
| Stock Repurchased | $5M | $2M | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | $2M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-5M | $-52M | $52M | $11M | · | $24M | · | $23M | $2M | |
| Net Change in Cash | $-8M | $45M | $-31M | $13M | · | $16M | $-2M | $1M | $62.0K | |
| Taxes Paid | · | $2M | · | $2M | · | · | $300.0K | · | $400.0K | |
| Free Cash Flow | $-9M | · | $-11M | $-28M | · | $-13M | $-13M | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.65% | · | · | · | · | · | · | · | · | |
| Operating Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| Net Margin | 3202.5% | · | 412.3% | -1397.1% | · | -424.8% | -531.1% | · | · | |
| Pretax Margin | 3766.2% | · | 379.7% | · | · | -424.8% | -520.0% | · | · | |
| EBITDA Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| ROA | 33.2% | · | 2.9% | -22.2% | · | -29.0% | -35.0% | · | · | |
| ROE | 37.0% | · | 3.5% | -23.7% | · | -47.0% | -70.1% | · | · | |
| ROIC | -6.4% | · | · | · | · | · | -67.6% | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.0 | · | 3.1 | 27.3 | · | 8.9 | 6.3 | · | · | |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · | 5.0 | 1.3 | · | · | |
| Debt / Equity | · | · | 0.3 | · | · | · | 0.1 | · | · | |
| Interest Coverage | · | · | -7.7 | · | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | · | 0.1 | 0.1 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $5.09 | · | $4.06 | $3.84 | · | $1.39 | $1.12 | · | · | |
| Revenue / Share | $0.05 | · | $0.03 | $0.07 | · | · | · | · | · | |
| Cash Flow / Share | $-0.22 | · | $-0.25 | $-0.72 | · | · | · | · | · | |
| Cash / Share | $1.17 | · | $0.22 | · | · | $0.81 | $0.19 | · | · | |
| Dividend Paid / Share | $0.25 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -50.4% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -9.6% | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $3M | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Net Income TTM | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| Market Cap | $112M | · | $93M | $476M | · | $83M | $58M | · | · | |
| Enterprise Value | · | · | $77M | · | · | · | $53M | · | · | |
| P/E | 1.9 | -5.0 | 16.5 | -12.8 | · | · | · | · | · | |
| P/S | 56.0 | · | 69.5 | 176.1 | · | 30.5 | 21.4 | · | · | |
| P/B | 0.6 | · | 0.6 | 3.1 | · | 2.5 | 3.0 | · | · | |
| P / Tangible Book | 0.6 | 0.7 | 0.6 | 3.1 | · | 2.5 | · | · | · | |
| P / Cash Flow | -12.2 | · | -9.1 | -17.0 | · | -6.6 | -4.5 | · | · | |
| P / FCF | -12.2 | · | -8.8 | -16.8 | · | -6.6 | -4.5 | · | · | |
| EV / EBITDA | · | · | -4.9 | · | · | · | -3.6 | · | · | |
| EV / FCF | · | · | -7.3 | · | · | · | -4.1 | · | · | |
| EV / Revenue | · | · | 57.8 | · | · | · | 19.8 | · | · | |
| Earnings Yield | 52.6% | -19.8% | 6.1% | -7.8% | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | · | · | $2M | · | · | · | · | $0 | · | $674.0K | $666.0K | $681.0K | $682.0K | |
| Cost of Revenue | · | · | $0 | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Gross Profit | · | · | $0 | · | · | $13.0K | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | · | $2M | $2M | $1M | $1M | $2M | $1M | $2M | $1M | $1M | $2M | $957.0K | $2M | $4M | $7M | $5M | |
| SG&A Expense | $3M | $2M | $4M | $1M | $1M | $2M | $2M | $847.0K | $2M | $2M | $2M | $3M | $2M | $1M | $3M | $3M | |
| Operating Expenses | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $11.0K | |
| Operating Income | $-3M | $-4M | $-6M | $-2M | $-2M | $-4M | $-4M | $-3M | $-3M | $-3M | $-4M | $-3M | $-4M | $-5M | $-10M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $592.0K | · | $826.0K | · | · | · | · | |
| Other Non-op | $-4.0K | $-100.0K | $-74M | $61M | · | $-143.0K | $-2M | $-15M | $14M | $4M | $-4M | $435.0K | $2M | $2M | $1M | $1M | |
| Pretax Income | $102M | $49M | $10M | $59M | $13M | $-7M | $-10M | $-19M | $11M | $2M | $13M | $-3M | $-1M | · | $-9M | $-7M | |
| Income Tax | $23M | $11M | $-212.0K | $11M | $-126.0K | $584.0K | $416.0K | $1M | $2M | · | · | · | · | · | $0 | $100.0K | |
| Net Income | $78M | $38M | $10M | $48M | $13M | $-8M | $-10M | $-20M | $9M | $2M | $13M | $-3M | $-1M | $-3M | $-8M | $-7M | |
| EPS (Basic) | $1.90 | $0.94 | $0.24 | $1.16 | $0.32 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| EPS (Diluted) | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| Shares (Basic) | 41,040,479 | 40,773,866 | · | 41,756,301 | 41,743,486 | 41,228,782 | · | 40,896,845 | 40,959,759 | 40,835,953 | · | 40,445,896 | 40,225,594 | 40,041,258 | · | 39,100,231 | |
| Shares (Diluted) | 42,501,252 | 41,970,186 | · | 42,774,504 | 42,609,425 | 41,228,782 | · | 40,896,845 | 41,591,007 | 41,564,007 | · | 40,445,896 | 40,225,594 | 40,041,258 | · | 39,100,231 | |
| EBITDA | $-3M | $-4M | · | $-2M | $-2M | $-4M | · | $-3M | $-3M | $-3M | · | $-3M | $-4M | $-5M | · | $-8M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $13M | $46M | $52M | $16M | · | $54M | · | $10M | $19M | · | · | · | · | $40M | · | |
| Short-term Investments | $846.0K | $5M | $5M | $5M | $2M | $4M | $3M | $57M | $66M | $78M | · | $49.4K | $943.0K | $2M | · | $5M | |
| Prepaid Expense | $2M | $2M | $3M | $1M | $1M | $832.0K | $1M | $474.0K | $533.0K | $501.0K | $537.0K | $666.0K | $769.0K | · | $1M | · | |
| Current Assets | $53M | $68M | $133M | $136M | $99M | $131M | $143M | $143M | $153M | $177M | $163M | $176M | $151M | $155M | $157M | $160M | |
| PP&E (Net) | $532.0K | $561.0K | $586.0K | $614.0K | $645.0K | $671.0K | $698.0K | $718.0K | $765.0K | $819.0K | $873.0K | $923.0K | $945.0K | $977.0K | $815.0K | $535.0K | |
| Other Non-current Assets | $49.0K | $46.0K | $44.0K | $40.0K | $38.0K | $32.0K | $32.0K | · | · | · | $27.0K | · | · | · | · | · | |
| Total Assets | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Accounts Payable | $374.0K | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | $5M | $3M | $1M | $551.0K | $3M | $828.0K | $4M | $4M | $4M | |
| Accrued Liabilities | $1M | $1M | $1M | $585.0K | $841.0K | $800.0K | $402.0K | · | · | · | $605.0K | · | · | · | · | · | |
| Short-term Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | $51M | $75M | $3.0K | $1.0K | · | · | |
| Current Liabilities | $11M | $11M | $19M | $6M | $4M | $5M | $6M | $5M | $4M | $34M | $53M | $78M | $1M | $5M | $6M | $7M | |
| Capital Leases | $484.0K | $493.0K | $540.0K | $589.0K | $648.0K | $120.0K | $156.0K | $186.0K | $236.0K | $272.0K | $342.0K | $389.0K | $488.0K | $564.0K | $647.0K | $672.0K | |
| Deferred Tax | $40M | $18M | $8M | $8M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $60.0K | $60.0K | $60.0K | · | $63.0K | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | $75M | · | · | · | $5M | |
| Total Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | · | $75M | $3.0K | $1.0K | · | · | |
| Common Stock | $495.0K | $491.0K | $472.0K | $490.0K | $491.0K | $491.0K | $480.0K | $484.0K | $488.0K | $487.0K | $485.0K | $484.0K | $484.0K | $481.0K | $476.0K | $470.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | · | $319M | $317M | · | $308M | |
| Retained Earnings | $-7M | $-85M | $-123M | $-123M | $-171M | $-184M | $-177M | $-166M | $-147M | $-156M | $-158M | $-171M | $-168M | $-166M | $-163M | $-155M | |
| Stockholders' Equity | $317M | $238M | $200M | $203M | $155M | $141M | $146M | $156M | $177M | $167M | $164M | $149M | $152M | $151M | $152M | $154M | |
| Liabilities + Equity | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Shares Outstanding | 41,314,211 | 40,926,081 | 39,275,006 | 40,838,226 | 40,845,087 | 40,850,455 | 39,919,545 | 40,209,575 | 40,628,924 | 40,519,160 | 40,338,979 | 40,282,688 | 40,219,396 | 39,969,979 | 39,563,888 | 39,113,236 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $2M | $2M | $719.0K | $800.0K | $2M | $1M | $301.0K | $1M | $1M | $1M | $852.0K | $2M | $173.0K | $3M | $3M | |
| Deferred Tax | $22M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-200.0K | $-3M | $-466.0K | $-2M | $-4M | $-4M | $-2M | $-7M | $2M | $-1M | $-1M | $-694.0K | $-3M | $-6M | $-8M | $-2M | |
| CapEx | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K | $0 | $2.0K | $3.0K | $32.0K | $20.0K | $199.0K | $308.0K | $121.0K | |
| Investing Cash Flow | $4M | $-19M | $-2M | $38M | $-55M | $24M | $15M | $-34M | $95M | $30M | $30M | $-75M | $-15M | $-13M | $11M | $1M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $-2.0K | $0 | $2M | $4M | $-3M | |
| Stock Repurchased | · | · | $4M | $361.0K | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Dividends Paid | $78.0K | $10M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-2M | $-10M | $-4M | $-361.0K | · | · | $-1M | $-1M | $-31M | $-19M | $-25M | $75M | $0 | $2M | $4M | $4M | |
| Net Change in Cash | $2M | $-33M | $-6M | $36M | $-59M | $20M | $12M | $-43M | $66M | $10M | $4M | $-1M | $-17M | $-16M | $7M | $3M | |
| Taxes Paid | · | · | · | $-7M | · | · | · | · | · | · | · | $527.0K | $3M | $308.0K | · | $167.0K | |
| Free Cash Flow | · | $-3M | · | · | · | $-4M | · | · | · | $-1M | · | · | · | $-6M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 0.65% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| Net Margin | · | · | · | · | · | -382.1% | · | · | · | · | · | · | -177.2% | -542.2% | · | -1063.5% | |
| Pretax Margin | · | · | · | · | · | -352.9% | · | · | · | · | · | · | · | · | · | -1048.8% | |
| EBITDA Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| ROA | 29.4% | 18.4% | · | 25.1% | 7.7% | -4.3% | · | -9.9% | 5.4% | 0.85% | · | -1.6% | -0.75% | -2.2% | · | -5.9% | |
| ROE | 33.1% | 20.2% | · | 26.9% | 8.0% | -5.0% | · | -12.8% | 5.6% | 0.97% | · | -2.1% | -0.78% | -2.3% | · | -6.5% | |
| ROIC | -0.67% | -1.2% | · | -0.97% | -1.6% | -3.5% | · | -2.1% | -1.5% | · | · | · | · | · | · | -5.4% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 6.5 | · | 22.2 | 26.8 | 23.9 | · | 27.1 | 41.1 | 5.3 | · | 2.2 | 141.5 | 31.2 | · | 24.5 | |
| Quick Ratio | 1.5 | 1.7 | · | 9.3 | 4.8 | 0.7 | · | 10.9 | 20.4 | 2.9 | · | 0.0 | 0.9 | 0.5 | · | 0.8 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | 0.2 | · | 0.5 | 0.0 | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -5.0 | · | -3.5 | · | · | · | · |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.68 | $5.82 | · | $4.98 | $3.78 | $3.45 | · | $3.89 | $4.36 | $4.11 | · | $3.70 | $3.77 | $3.78 | · | $3.93 | |
| Revenue / Share | · | · | · | · | · | $0.05 | · | · | · | · | · | · | $0.02 | $0.02 | · | $0.02 | |
| Cash Flow / Share | · | $-0.07 | · | · | · | $-0.09 | · | · | · | $-0.04 | · | · | · | $-0.14 | · | · | |
| Cash / Share | $0.37 | $0.32 | · | $1.28 | $0.39 | · | · | · | $0.25 | $0.46 | · | · | · | · | · | · | |
| EPS (TTM) | $4.13 | $2.60 | · | $0.99 | $-0.62 | $-0.71 | · | $0.11 | $0.51 | $0.26 | · | $-1.85 | $-1.59 | $-1.29 | · | · |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | |
| Net Income TTM | $175M | $110M | · | $44M | $-24M | $-28M | · | $4M | $20M | $10M | · | $-16M | $-20M | $-29M | · | $-36M | |
| Market Cap | $199M | $139M | · | $108M | $92M | $87M | · | $98M | $104M | $118M | · | $105M | $144M | $87M | · | $253M | |
| Enterprise Value | · | · | · | $51M | $74M | · | · | · | · | $54M | · | · | · | · | · | · | |
| P/E | 1.2 | 1.3 | · | 2.7 | -3.6 | -3.0 | · | 22.2 | 5.0 | 11.2 | · | -1.4 | -2.3 | -1.7 | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 38.9 | 53.3 | 32.2 | · | 94.0 | |
| P/B | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Tangible Book | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Cash Flow | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.2 | · | · | · | -15.7 | · | · | |
| Earnings Yield | 85.9% | 76.5% | · | 37.5% | -27.6% | -33.2% | · | 4.5% | 19.8% | 8.9% | · | -70.9% | -44.4% | -59.2% | · | · | |
| Payout Ratio | · | 27.1% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $2M | · | $1M | $3M | · |
| Brüt Kâr Marjı % | 0.65% | · | · | · | · |
| Faaliyet Kâr Marjı % | -754.4% | · | -1176.8% | -1502.0% | · |
| Net Gelir | $64M | $-19M | $5M | $-37M | · |
| Seyreltilmiş Hisse Başı Kâr | $1.50 | $-0.48 | $0.14 | $-0.94 | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | · | · | 0.3 | · | · |
| Cari Oran | 7.0 | · | 3.1 | 27.3 | · |
| Cari Oran | 2.7 | · | 1.3 | 0.7 | · |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-9M | · | $-11M | $-28M | · |
Kurumsal Sahipler (13F) 87 dosya · $85.5M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
87
Tutulan Değer
$85.5M
Yeni pozisyonlar
30
Çıkan pozisyonlar
8
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 30 (+13 önceki Ç'ye göre) | 8 (0 önceki Ç'ye göre) | 21 (+2 önceki Ç'ye göre) | 19 (+4 önceki Ç'ye göre) | +3.6M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | $18.328.697 | 3.810.540 | 21,43% | Hisse senetleri |
| Aquamarine Financial (Cayman) Ltd | $12.083.562 | 2.512.175 | 14,13% | Hisse senetleri |
| Gem Investment Advisors, LLC | $9.614.238 | 1.998.802 | 11,24% | Hisse senetleri |
| BlackRock, Inc. | $7.735.015 | 1.608.111 | 9,04% | Hisse senetleri |
| Murchinson Ltd. | $6.206.314 | 1.290.294 | 7,26% | Hisse senetleri |
| SB Capital Management Inc | $5.415.000 | 1.900.000 | 6,33% | Hisse senetleri |
| BML Capital Management, LLC | $4.166.754 | 866.269 | 4,87% | Hisse senetleri |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.783.249 | 578.638 | 3,25% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $2.408.318 | 500.690 | 2,82% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $1.218.339 | 253.293 | 1,42% | Hisse senetleri |
| STATE STREET CORP | $1.164.501 | 242.100 | 1,36% | Hisse senetleri |
| Rathbones Group PLC | $1.120.816 | 233.018 | 1,31% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.105.732 | 229.882 | 1,29% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $973.782 | 202.609 | 1,14% | Hisse senetleri |
| NORTHERN TRUST CORP | $889.465 | 184.920 | 1,04% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $884.078 | 183.800 | 1,03% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $798.458 | 166.000 | 0,93% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $724.838 | 150.694 | 0,85% | Hisse senetleri |
| STRS OHIO | $643.578 | 133.800 | 0,75% | Hisse senetleri |
| JANE STREET GROUP, LLC | $545.209 | 113.349 | 0,64% | Hisse senetleri |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $495.247 | 102.962 | 0,58% | Hisse senetleri |
| MARSHALL WACE, LLP | $490.393 | 101.953 | 0,57% | Hisse senetleri |
| Hillsdale Investment Management Inc. | $429.533 | 89.300 | 0,50% | Hisse senetleri |
| RITHOLTZ WEALTH MANAGEMENT | $405.709 | 84.347 | 0,47% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $402.280 | 83.634 | 0,47% | Hisse senetleri |
| Bank of New York Mellon Corp | $381.217 | 79.255 | 0,45% | Hisse senetleri |
| UBS Group AG | $325.498 | 67.671 | 0,38% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $287.518 | 59.775 | 0,34% | Hisse senetleri |
| XTX Topco Ltd | $240.130 | 49.923 | 0,28% | Hisse senetleri |
| Nuveen, LLC | $223.203 | 46.404 | 0,26% | Hisse senetleri |
| MORGAN STANLEY | $208.547 | 43.357 | 0,24% | Hisse senetleri |
| CITADEL ADVISORS LLC | $199.927 | 41.565 | 0,23% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $159.682 | 33.198 | 0,19% | Hisse senetleri |
| PRELUDE CAPITAL MANAGEMENT, LLC | $157.350 | 32.713 | 0,18% | Hisse senetleri |
| BAILARD, INC. | $156.219 | 32.478 | 0,18% | Hisse senetleri |
| RHUMBLINE ADVISERS | $147.281 | 30.621 | 0,17% | Hisse senetleri |
| ALGERT GLOBAL LLC | $139.288 | 28.958 | 0,16% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $121.246 | 25.207 | 0,14% | Hisse senetleri |
| CITADEL ADVISORS LLC | $120.250 | 25.000 | 0,14% | Alım opsiyonu |
| Invesco Ltd. | $119.052 | 24.751 | 0,14% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $107.263 | 22.300 | 0,13% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $105.151 | 21.861 | 0,12% | Hisse senetleri |
| PNC Financial Services Group, Inc. | $101.972 | 21.200 | 0,12% | Hisse senetleri |
| Redwood Family Wealth LLC | $99.783 | 20.745 | 0,12% | Hisse senetleri |
| Sage Capital Management, LLC | $86.474 | 17.977 | 0,10% | Hisse senetleri |
| CITIGROUP INC | $76.037 | 15.808 | 0,09% | Hisse senetleri |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $75.378 | 15.671 | 0,09% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $67.811 | 14.098 | 0,08% | Hisse senetleri |
| JPMORGAN CHASE & CO | $65.693 | 14.158 | 0,08% | Hisse senetleri |
| Y-Intercept (Hong Kong) Ltd | $61.650 | 12.817 | 0,07% | Hisse senetleri |
Aktivistler ve %5+ sahipler 9 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | 22 Temmuz 2026 | 3,30% | Değişiklik | · | SEC |
| Nadav Kidron ×8 başvurular | 28 Ağustos 2025 | 7,60% | Değişiklik | · | SEC |
| Regals Capital Management LP, Regals Fund LP, David M. Slager ×2 başvurular | 20 Temmuz 2018 | · | İlk başvuru | · | SEC |
| Hefei Tianhui Incubator of Technologies Co., Ltd | 06 Ocak 2016 | · | İlk başvuru | · | SEC |
| Leonard Sank | 15 Aralık 2014 | · | İlk başvuru | Pasif yatırım | SEC |
| Miriam Kidron ×2 başvurular | 03 Şubat 2014 | · | İlk başvuru | · | SEC |
| Zeev Bronfeld | 06 Mart 2006 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 10 Haziran 2004 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 10 Haziran 2004 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 30 içeriden öğrenenler · 13 yöneticiler · 16 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Nadav Kidron | President and CEO | 24 Eylül 2026 D | 4.140.505 | 0 | 0 | $0 |
| Avraham Gabay | Chief Financial Officer | 01 Ekim 2026 S | 861.076 | 0 | 2 | $-421.054 |
| David Silberman | Chief Financial Officer | 04 Ocak 2024 A | 366.500 | 0 | 0 | $0 |
| Hilla Eisenberg | CFO, Treasurer and Secretary | 26 Şubat 2019 A | · | 0 | 0 | $0 |
| Yifat Hen Zommer | CFO, Treasurer and Secretary | 30 Haziran 2017 A | 46.560 | 0 | 0 | $0 |
| Chaime Orlev | CFO, Treasurer and Secretary | 12 Ekim 2008 A | · | 0 | 0 | $0 |
| Joshua Hexter | COO & CBO | 01 Ekim 2026 S | 1.328.130 | 0 | 2 | $-746.320 |
| Miriam Kidron | Chief Scientific Officer | 24 Eylül 2026 D | 1.550.554 | 0 | 0 | $0 |
| Netanel Derovan | Chief Legal Officer | 26 Mayıs 2023 A | 149.500 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 03 Ocak 2023 S | 126.143 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 03 Ocak 2022 A | 109.468 | 0 | 0 | $0 |
| Mark Daniel Hasleton | VP Business Development | 26 Şubat 2019 A | · | 0 | 0 | $0 |
| Ronald Edward Law | Chief Strategy Officer | 20 Mart 2017 A | · | 0 | 0 | $0 |
| Yehuda Reznick | Yönetim kurulu üyesi | 31 Aralık 2025 A | 105.180 | 0 | 0 | $0 |
| Daniel Aghion | Yönetim kurulu üyesi | 31 Aralık 2025 A | 113.441 | 0 | 0 | $0 |
| Benjamin Shapiro | Yönetim kurulu üyesi | 31 Aralık 2025 A | 123.220 | 0 | 0 | $0 |
| Arie Mayer | Yönetim kurulu üyesi | 31 Aralık 2025 A | 168.009 | 0 | 0 | $0 |
| Leonard Sank | Yönetim kurulu üyesi | 05 Haziran 2025 A | 134.531 | 0 | 0 | $0 |
| Yadin Rozov | Yönetim kurulu üyesi | 04 Ocak 2024 A | 155.320 | 0 | 0 | $0 |
| Kevin Rakin | Yönetim kurulu üyesi | 21 Mart 2022 S | 46.661 | 0 | 0 | $0 |
| Aviad Friedman | Yönetim kurulu üyesi | 03 Ocak 2022 G | 0 | 0 | 0 | $0 |
| Gao Xiaoming | Yönetim kurulu üyesi | 08 Ocak 2020 A | · | 0 | 0 | $0 |
| David Mark Slager | Yönetim kurulu üyesi | 15 Nisan 2019 A | 1.316.328 | 0 | 0 | $0 |
| Xiaopeng Li | Yönetim kurulu üyesi | 02 Ağustos 2017 P | 206.350 | 0 | 0 | $0 |
| Harold Jacob | Yönetim kurulu üyesi | 10 Mart 2016 S | 16.396 | 0 | 0 | $0 |
| Michael Berelowitz | Yönetim kurulu üyesi | 09 Aralık 2015 S | 22.896 | 0 | 0 | $0 |
| Gerald M Ostrov | Yönetim kurulu üyesi | 23 Şubat 2015 A | 24.896 | 0 | 0 | $0 |
| REGALS CAPITAL MANAGEMENT LP | 10% sahip | 23 Aralık 2015 X | 1.186.823 | 0 | 0 | $0 |
| Zeev Bronfeld | 10% sahip | 27 Eylül 2011 S | 5.808.517 | 0 | 0 | $0 |
| Michael Young | · | 27 Mayıs 2004 S | 0 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 13 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IWC · iShares Trust | 0,04% | 117.335 SH | 11 Eylül 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 7.007 SH | 30 Eylül 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29.637 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,00% | 16.237 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,00% | 622.970 SH | 11 Eylül 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,00% | 40.483 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 4.523 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.536 NS | 31 Temmuz 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 3.431 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 196.765 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.480 SH | 19 Ağustos 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,00% | 4 NS | 31 Temmuz 2026 | N-PORT |
| IWN · iShares Trust | · | 316.654 SH | 11 Eylül 2026 | Günlük |
ORMP Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 6 analist
SAT
Medyan hedef
$7.00
+55,9%
0 0,0%
Güçlü Al
0 0,0%
Al
3 50,0%
Tut
1 16,7%
Sat
2 33,3%
Güçlü Sat
12 Aylık Fiyat Hedefi
1 analist · 2026-09-29Ortalama hedef $7.00 +55,9%
Düşük$7.00
Ortalama$7.00
Yüksek$7.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 10, 2026